SEC Form 4 · accession 0001604689-17-000004
GENOCEA BIOSCIENCES, INC. · GNCA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jonathan Poole
Officer — Chief Financial Officer
Period of report
May 3, 2017
Accepted (ET)
May 10, 2017 · 4:44 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001457612
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 3, 2017 | A | 7,937 | $0.00 | A | 25,150 | D | |
| Common StockF2 | May 3, 2017 | A | 23,810 | $0.00 | A | 48,960 | D | |
| Common StockF3 | May 8, 2017 | S | 6,213 | $6.51 | D | 42,747 | D | |
| Common Stock | May 10, 2017 | F | 3,500 | $6.13 | D | 39,247 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The restricted stock units ("RSUs") were granted in accordance with Genocea Biosciences, Inc.'s (the "Company") 2014 Equity Incentive Plan (the "Plan") and vested immediately upon grant.
- F2The RSUs were granted in accordance with the Plan and will vest in full 18 months from the grant date, subject to Mr. Poole's continued employment with the Company.
- F3The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $6.50 to $6.54, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F4Shares sold to cover taxes on RSUs that vested on May 3, 2017.